Hyperfine Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Hyperfine's earnings have been declining at an average annual rate of -10.4%, while the Medical Equipment industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 64.4% per year.
Belangrijke informatie
-10.4%
Groei van de winst
70.1%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 8.9% |
| Inkomstengroei | 64.4% |
| Rendement op eigen vermogen | -62.1% |
| Nettomarge | -347.1% |
| Volgende winstupdate | 12 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Hyperfine appoints Maria Sainz as President, CEO
Oct 06Hyperfine GAAP EPS of -$0.33 misses by $0.06, revenue of $1.53M misses by $0.47M
Aug 10Hyperfine stock plunges 14% as CEO Dave Scott steps down
Jun 29Hyperfine (NASDAQ:HYPR) Is In A Good Position To Deliver On Growth Plans
Apr 04
Hyperfine: MR Imaging In A Swoop
Mar 09Opbrengsten en kosten
Hoe Hyperfine geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 12 | -41 | 27 | 23 |
| 31 Mar 24 | 12 | -42 | 28 | 23 |
| 31 Dec 23 | 11 | -44 | 30 | 22 |
| 30 Sep 23 | 10 | -47 | 32 | 22 |
| 30 Jun 23 | 10 | -49 | 32 | 23 |
| 31 Mar 23 | 8 | -62 | 40 | 25 |
| 31 Dec 22 | 7 | -73 | 47 | 28 |
| 30 Sep 22 | 6 | -86 | 55 | 32 |
| 30 Jun 22 | 4 | -89 | 58 | 31 |
| 31 Mar 22 | 3 | -81 | 50 | 30 |
| 31 Dec 21 | 1 | -65 | 38 | 26 |
| 30 Sep 21 | 1 | -46 | 24 | 21 |
| 30 Jun 21 | 1 | -35 | 17 | 18 |
| 31 Mar 21 | 1 | -26 | 10 | 15 |
| 31 Dec 20 | 0 | -23 | 8 | 15 |
Kwaliteitswinsten: HYPR is currently unprofitable.
Groeiende winstmarge: HYPR is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: HYPR is unprofitable, and losses have increased over the past 5 years at a rate of 10.4% per year.
Versnelling van de groei: Unable to compare HYPR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: HYPR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).
Rendement op eigen vermogen
Hoge ROE: HYPR has a negative Return on Equity (-62.08%), as it is currently unprofitable.